NCT04476459 2021-03-15Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLSun Yat-sen UniversityPhase 1/2 Unknown33 enrolled
NCT03376958 2019-07-25Apatinib for Relapsed and Refractory Diffuse Large B Cell LymphomaZhengzhou UniversityPhase 4 Completed32 enrolled